Get the Stockscreener App
1.01
0.00%
0.00
After Hours:
.96
-0.05
-4.95%
Scisparc Ltd stock is traded at $1.01, with a volume of 85,190.
It is up +0.00% in the last 24 hours and down -27.34% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$1.01
Open:
$0.9621
24h Volume:
85,190
Relative Volume:
0.04
Market Cap:
$4.39M
Revenue:
$1.31M
Net Income/Loss:
$-7.47M
P/E Ratio:
-0.1401
EPS:
-7.2117
Net Cash Flow:
$-5.11M
1W Performance:
-5.61%
1M Performance:
-27.34%
6M Performance:
-87.38%
1Y Performance:
+71.80%
1-Day Range:
$0.96
$1.01
1-Week Range:
$0.96
$1.145
52-Week Range:
$0.226
$8.90
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
1.01 | 4.39M | 1.31M | -7.47M | -5.11M | -7.2117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
814.74 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.98 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.32 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Scisparc Ltd Stock (SPRC) Latest News
Big Money Moves: Is Funko Inc part of any ETFJuly 2025 Chart Watch & Fast Momentum Entry Tips - baoquankhu1.vn
Aug Wrap: Should you buy the dip on Rithm Acquisition Corp Debt Equity Composite UnitsWeekly Trade Analysis & Community Consensus Trade Alerts - baoquankhu1.vn
SciSparc receives Nasdaq notice over stockholders’ equity shortfall - MSN
Gainers Report: Is SciSparc Ltd backed by strong institutional buyingDollar Strength & AI Driven Price Predictions - baoquankhu1.vn
SPRC Stock Price, Forecast & Analysis | SCISPARC LTD (NASDAQ:SPRC) - Chartmill
Short Covering: What drives SciSparc Ltd.’s stock price2025 Key Lessons & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Form 424B5 SciSparc Ltd. - StreetInsider
SciSparc Receives Nasdaq Notice Over Minimum Stockholders’ Equity Non-Compliance - The Globe and Mail
SciSparc to acquire MUSE endoscopic system patents from Xylo By Investing.com - Investing.com Nigeria
SciSparc to Acquire Endoscopic Device Patents Targeting $3B Market - Meyka
SciSparc Moves Into Endoscopy With Strategic Patent Deal - Benzinga
SciSparc Ltd. (SPRC) stock: dips nearly 12% as company unveils strategic MUSE™ endoscopic technology acquisition - parameter.io
SciSparc Faces Nasdaq Non-Compliance Challenge Over Stockholders’ Equity - StocksToTrade
SciSparc to acquire MUSE endoscopic system patents from Xylo - Investing.com
SciSparc Faces Nasdaq Noncompliance: Struggles Loom - StocksToTrade
SciSparc Launches $766,170 Registered Direct Share Offering - TipRanks
SciSparc Signs Agreement To Acquire Patent Portfolio For Endoscopic Technologies; Stock Soars - Nasdaq
SciSparc Subsidiary to Acquire Endoscopic Patents of Xylo Technologies in All-Stock Deal - marketscreener.com
SciSparc to Acquire Xylo GERD Device IP in Share-Based Deal, Targeting Global Endoscope Market - TipRanks
SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity - The Manila Times
Whittier Daily News - FinancialContent
SciSparc receives Nasdaq non-compliance notice for stockholders’ equity By Investing.com - Investing.com Nigeria
SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
SciSparc receives Nasdaq non-compliance notice for stockholders’ equity - Investing.com
SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance - The Manila Times
SciSparc Ltd. Receives Nasdaq Notification of Non-Compliance with Stockholders' Equity Requirement - Quiver Quantitative
Is SciSparc Ltd. stock oversold or undervaluedChart Signals & Low Drawdown Momentum Ideas - Улправда
Breakout Zone: How SciSparc Ltd stock benefits from global expansionJuly 2025 Intraday Action & Growth Focused Investment Plans - Bộ Nội Vụ
Published on: 2026-01-09 12:53:14 - Улправда
Why SciSparc Ltd. stock remains on watchlistsJuly 2025 WrapUp & Growth Focused Stock Reports - Улправда
Why SciSparc Ltd. stock is seen as undervalued2025 Market Sentiment & Growth-Oriented Investment Plans - Улправда
Neurothera Labs Announces Results of AGM - TheNewswire
VIX Spike: Why SciSparc Ltd. stock remains a top recommendationJuly 2025 Outlook & Free Fast Gain Swing Trade Alerts - Улправда
How strong is SciSparc Ltd. stock revenue growthMarket Sentiment Report & AI Enhanced Trading Alerts - Улправда
Why SciSparc Ltd. stock remains a top recommendation2025 Growth vs Value & Daily Chart Pattern Signals - Улправда
Can SciSparc Ltd. stock deliver strong Q4 earningsStop Loss Placement Tips & Small Investment Capital Tips - Улправда
SciSparc says Neurothera Labs granted patent by Israeli Patent Office - MSN
What drives SciSparc Ltd stock priceHigh Dividend Yield Stocks & Small Budget Capital Growth - Early Times
Libord Securities Limited Testing Reversal Zone on Weekly ChartMarket Sentiment Report & Outstanding Investment Returns - earlytimes.in
What analysts say about SciSparc Ltd stockStock Correlation Metrics & Daily Tips From Top Market Analysts - earlytimes.in
SciSparc Calls February 2026 Meeting to Approve New Deloitte Auditor and Executive Equity Awards - The Globe and Mail
SciSparc’s subsidiary NeuroThera receives patent in Israel for opioid tech By Investing.com - Investing.com Nigeria
SciSparc’s subsidiary NeuroThera receives patent in Israel for opioid tech - Investing.com India
SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects - The Manila Times
SciSparc Ltd.'s Majority-Owned NeuroThera Labs Receives Patent for Opioid-N-acylethanolamine Combination to Enhance Pain Management - Quiver Quantitative
SciSparc: Neurothera Labs Granted Patent by Israeli Patent - GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Aug Catalysts: How SciSparc Ltd stock benefits from global expansionDividend Hike & High Accuracy Buy Signal Tips - moha.gov.vn
CEO Moves: Is Venture Global Inc. stock a good choice for value investorsJuly 2025 Trade Ideas & Risk Controlled Swing Alerts - moha.gov.vn
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.92%
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):